Stevens-Johnson Syndrome Clinical Trial
Official title:
Stevens-Johnson Syndrome Associated With Antimicrobial
Verified date | February 2009 |
Source | University of Pernambuco |
Contact | n/a |
Is FDA regulated | No |
Health authority | Brazil: Ethics Committee |
Study type | Observational |
Steven-Johnson's syndrome, or great multiform erythema, appears as a systemic disturbance, with skin involvement and mucous membranes, related to several factors, such as, viral or bacterial infections and mainly the administration of medicines, in general painkillers and antibiotics. The objective of this work is report the emergence of ulcerative vesicle -bubble chronic disease in areas of lips, gum, tongue and genital mucous membrane in a 26 year-old patient, leucoderma and masculine gender, in treatment of breathing infection with sulfametoxazol-trimetropima, having been diagnosed as syndrome of Steven-Johnson.
Status | Completed |
Enrollment | 1 |
Est. completion date | December 2008 |
Est. primary completion date | August 2008 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 20 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Stevens-Johnson syndrome associated with antimicrobial Exclusion Criteria: - Not sick |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Brazil | University of Pernambuco | Recife | Pernambuco |
Lead Sponsor | Collaborator |
---|---|
University of Pernambuco |
Brazil,
Vanfleteren I, Van Gysel D, De Brandt C. Stevens-Johnson syndrome: a diagnostic challenge in the absence of skin lesions. Pediatr Dermatol. 2003 Jan-Feb;20(1):52-6. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03659227 -
Drug Reactions Sampling (COLLECTIONTOXIDERMIES)
|
||
Completed |
NCT01696500 -
Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
|
Phase 3 | |
Terminated |
NCT02037347 -
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02126020 -
Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05520086 -
Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.
|
Phase 1/Phase 2 | |
Completed |
NCT06263140 -
Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study
|
||
Available |
NCT02149732 -
Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT05284929 -
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
|
||
Recruiting |
NCT02987257 -
NATIENS: Optimal Management and Mechanisms of SJS/TEN
|
Phase 3 | |
Completed |
NCT02945176 -
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation
|
N/A | |
Not yet recruiting |
NCT03585946 -
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
|
||
Recruiting |
NCT04313725 -
Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease
|
N/A | |
Recruiting |
NCT03046914 -
HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction
|
N/A | |
Completed |
NCT01488396 -
Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye
|
Phase 4 | |
Withdrawn |
NCT01256489 -
Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01122303 -
Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye
|
N/A | |
Recruiting |
NCT05145959 -
Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
|
N/A |